Enlivex to Present at Upcoming Investor and Media Conferences

Rhea-AI Summary

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced its participation in multiple investor conferences in September 2022. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 11:00 AM ET, and at Baird’s 2022 Global Healthcare Conference on September 14, 2022, at 3:10 PM ET. Additionally, Enlivex will engage in a panel discussion at the Cantor Cell and Genetic Medicines Conference on September 15, 2022, at 9:20 AM ET. Management will also be available for one-on-one meetings during these events.

Nes-Ziona, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will be presenting at the following investor and media conferences in September. 

H.C. Wainwright 24^th Annual Global Investment Conference

Presentation Format:	Corporate Presentation
Date & Time:	September 13, 2022, at 11:00 AM ET
Location:	Lotte New York Palace Hotel
Webcast Link:	Here

Baird’s 2022 Global Healthcare Conference

Presentation Format:	Corporate Presentation
Date & Time:	September 14, 2022, at 3:10 PM ET
Location:	InterContinental New York Barclay
Webcast Link:	Here

Cantor Cell and Genetic Medicines Conference

Presentation Format:	Panel Discussion
Panel Title:	CAR-T and Beyond: What Are the Next Generation Cell Therapies?
Date & Time:	September 15, 2022, at 9:20 AM ET
Location:	Lotte New York Palace Hotel

Company management will be available for 1x1 investor meetings during the Cantor and H.C. Wainwright events. Those interested in requesting a meeting during the conferences should contact their respective event representative.

ABOUT ENLIVEX

Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit https://enlivex.com/.

ENLIVEX CONTACT                                                                            
Shachar Shlosberger, CFO                                                                    
Enlivex Therapeutics, Ltd.                                                                      
shachar@enlivexpharm.com

INVESTOR RELATIONS CONTACT
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com

FAQ

What conferences will Enlivex Therapeutics participate in September 2022?

Enlivex Therapeutics will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, the Baird’s 2022 Global Healthcare Conference on September 14, and participate in a panel discussion at the Cantor Cell and Genetic Medicines Conference on September 15.

When is Enlivex's presentation at the H.C. Wainwright Conference?

Enlivex's presentation at the H.C. Wainwright 24th Annual Global Investment Conference is scheduled for September 13, 2022, at 11:00 AM ET.

What topics will Enlivex discuss at the Cantor Cell and Genetic Medicines Conference?

At the Cantor Cell and Genetic Medicines Conference, Enlivex will participate in a panel discussion titled 'CAR-T and Beyond: What Are the Next Generation Cell Therapies?' on September 15, 2022, at 9:20 AM ET.

How can investors meet with Enlivex management during the conferences?

Investors interested in one-on-one meetings with Enlivex management during the conferences should contact the respective event representatives.